Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Deferred Revenue: 2022-2025

Historic Current Deferred Revenue for BridgeBio Pharma (BBIO) over the last 4 years, with Sep 2025 value amounting to $9.1 million.

  • BridgeBio Pharma's Current Deferred Revenue fell 22.80% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year decrease of 22.80%. This contributed to the annual value of $14.6 million for FY2024, which is 139.57% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Current Deferred Revenue is $9.1 million, which was down 13.79% from $10.5 million recorded in Q2 2025.
  • BridgeBio Pharma's Current Deferred Revenue's 5-year high stood at $15.1 million during Q2 2024, with a 5-year trough of $6.1 million in Q4 2023.
  • Its 3-year average for Current Deferred Revenue is $10.2 million, with a median of $10.5 million in 2025.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first spiked by 143.12% in 2024, then plummeted by 30.19% in 2025.
  • Quarterly analysis of 4 years shows BridgeBio Pharma's Current Deferred Revenue stood at $8.2 million in 2022, then declined by 25.26% to $6.1 million in 2023, then skyrocketed by 139.57% to $14.6 million in 2024, then declined by 22.80% to $9.1 million in 2025.
  • Its last three reported values are $9.1 million in Q3 2025, $10.5 million for Q2 2025, and $11.6 million during Q1 2025.